A Risk-Adapted Framework for Adjuvant Pembrolizumab Plus Belzutifan in Resected Clear Cell Renal Cell Carcinoma
Year: 2026
Type: article
Source: Clinical Genitourinary Cancer
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: U.S. Department of Defense
OpenAlex ID: W7212921310